foxo4 dri senolytic peptide human trial 2024 2025 Interventions for Type 2 Diabetes: Current Evidence and Future Directions Frontiers | FOXO4-DRI regulates endothelial
Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway Frontiers Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Full article: Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $6.81 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8





